BioMarin Pharmaceuticals (BMRN)

• Market cap: $11.4B
• 1 day: 0.60%
• 5 days: 4.01%
• 1 month: -17.30%
• 3 months: -3.84%
• 6 months: -14.83%
• Year to date: -11.01%
• 1 year: -34.60%
• 5 years: -33.61%
• 10 years: -51.06%
• Sector: Healthcare
• Industry: Biotechnology

About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Employees: 3,040

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]

3.24% more ownership

Funds ownership: 92.84% [Q3] → 96.08% (+3.24%) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 181

10% more call options, than puts

Call options by funds: $141M | Put options by funds: $128M

2% less first-time investments, than exits

New positions opened: 89 | Existing positions closed: 91

3% less capital invested

Capital invested by funds: $12.4B [Q3] → $12B (-$383M) [Q4]

2% less funds holding

Funds holding: 544 [Q3] → 531 (-13) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 18% upside
• Avg. target: $95 61% upside
• High target: $126 113% upside

8 analyst ratings

• positive: 5 63%
• neutral: 3 38%
• negative: 0 0%

Oppenheimer Leland Gershell 39% 1-year accuracy 18 / 46 met price target	66% upside $98	Outperform Upgraded	24 Feb 2025
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target	35% upside $80	Sector Perform Maintained	20 Feb 2025
Citigroup David Lebovitz 63% 1-year accuracy 10 / 16 met price target	39% upside $82	Neutral Maintained	20 Feb 2025
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target	18% upside $70	Sector Perform Reiterated	20 Feb 2025
Cantor Fitzgerald Olivia Brayer 53% 1-year accuracy 10 / 19 met price target	52% upside $90	Overweight Reiterated	20 Feb 2025